Karyopharm therapeutics inc. (KPTI)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Revenues:
Total revenues

40,893

30,336

1,605

154

250

-

-

-

-

Contract and grant revenue

-

-

-

-

-

229

387

634

152

Operating expenses:
Cost of sales

2,407

-

-

-

-

-

-

-

-

Research and development

122,340

161,372

107,273

86,938

97,744

60,127

28,452

14,095

8,623

Selling, general and administrative

105,421

48,847

24,870

-

-

-

-

-

-

General and administrative

-

-

-

23,948

21,582

15,948

5,885

2,429

1,840

Total operating expenses

230,168

210,219

132,143

110,886

119,326

76,075

34,337

16,524

10,463

Loss from operations

-189,275

-179,883

-130,538

-110,732

-119,076

-75,846

-33,950

-15,890

-10,311

Other income (expense):
Interest income

5,422

4,028

1,698

1,284

897

97

3

2

-

Interest expense

15,647

2,493

-

-

-

1

-

-

-

Other income (expense), net

-50

-33

-81

10

-2

-27

-

2

-

Total other expense, net

-10,275

1,502

1,617

1,294

895

69

3

-

-

Loss before income taxes

-199,550

-178,381

-128,921

-109,438

-118,181

-75,777

-

-

-

Income tax provision

40

26

63

139

-

-

-

-

-

Net loss

-199,590

-178,407

-128,984

-109,577

-118,181

-75,777

-33,947

-15,888

-10,311

Net loss per share—basic and diluted

-3.22

-3.14

-2.81

-2.92

-3.32

-2.43

-5.59

-8.95

-10.27

Weighted-average number of common shares outstanding used in net loss per share—basic and diluted

61,955

56,799

45,899

37,523

35,619

31,135

6,067

1,775

1,004

Product revenue
Total revenues

30,540

-

-

-

-

-

-

-

-

License and other revenue
Total revenues

10,353

30,336

1,605

-

-

-

-

-

-